Viking Therapeutics (VKTX) Competitors

Viking Therapeutics (NASDAQ:VKTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Which has stronger valuation & earnings, VKTX or ASND?

Viking Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$109.96M	-$1.15	-25.65
Ascendis Pharma A/S	$368.70M	28.57	-$409.12M	-$6.28	-27.51

Do insiders and institutionals have more ownership in VKTX or ASND?

76.0% of Viking Therapeutics shares are held by institutional investors. 4.1% of Viking Therapeutics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is VKTX or ASND more profitable?

Viking Therapeutics has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -104.54%. Ascendis Pharma A/S's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-11.93%	-11.57%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Do analysts rate VKTX or ASND?

Viking Therapeutics presently has a consensus target price of $87.15, indicating a potential upside of 195.49%. Ascendis Pharma A/S has a consensus target price of $217.73, indicating a potential upside of 26.05%. Given Viking Therapeutics' higher possible upside, equities analysts clearly believe Viking Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor VKTX or ASND?

Viking Therapeutics received 179 more outperform votes than Ascendis Pharma A/S when rated by MarketBeat users. Likewise, 80.08% of users gave Viking Therapeutics an outperform vote while only 67.26% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
Viking Therapeutics	Outperform Votes 635 80.08%	Underperform Votes 158 19.92%
Ascendis Pharma A/S	Outperform Votes 456 67.26%	Underperform Votes 222 32.74%

Which has more volatility & risk, VKTX or ASND?

Viking Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Does the media favor VKTX or ASND?

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Viking Therapeutics. MarketBeat recorded 13 mentions for Ascendis Pharma A/S and 12 mentions for Viking Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.01 beat Viking Therapeutics' score of 0.81 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Viking Therapeutics beats Ascendis Pharma A/S on 10 of the 17 factors compared between the two stocks.